News

A new study found states that offered monetary prizes to randomly selected vaccinated persons did not have significant increases in vaccine uptake.

Underweight elderly pneumonia patients were more likely to contract C difficile infection.

Novavax’s COVID-19 vaccine demonstrated 90.4% efficacy in a phase 3 trial with no moderate or severe cases reported among participants in the treatment group.

The country says one city hospital’s data shows a decrease in severity and mortality during this latest variant's outbreak.

The FDA now recommends Americans 12 years and older receive COVID-19 booster shots. Additionally, they moved to shorten the time in between the second and third dose from 6 months to 5 for Pfizer-BioNTech recipients.

Immigrant communities may be more hesitant to disclose personal health information due to fears of bullying or deportation, a new study finds.

Investigators compared pre- and post-intervention data points at 4 clinics in Kenya.

Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.

The fast-moving Omicron variant demonstrates a high transmissibility, but not as significant a hospitalization rate or mortality.

COVID-19 patients who underwent prior weight-loss surgery were significantly less likely to experience severe disease outcomes.

The US is on track to reach new records for 7-day average cases, though death rates remain lower.

A phase 3 trial shows one dose is 91.7 % effective against severe disease.

The oral antiviral therapy proceeds the first indication for the drug class by just a day; the US will now have multiple pills to treat COVID-19.

In a study of more than 600 elderly Japanese, being overweight was a protective factor against Clostridioides difficile infection (CDI).

Risk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.

Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP are aiming to increase users.

This is the first pill to treat COVID-19 in trying to prevent progression to severe disease and possible hospitalization.

COVID-19 patients were not at increased risk of Clostridium difficile infection. However, those already infected with C diff were more likely to experience severe outcomes.

A study of mRNA vaccination in older people and people with comorbidities found vaccine efficacy of 69% against COVID-19 infection and 86% against death.

This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.

The administration is going to buy 500 million at-home rapid COVID-19 tests, and make them available to Americans. They also plan to use federal resources to provide pop-up clinics and get more pharmacists involved in vaccinations.

Here’s where you should sit on the bus to avoid COVID-19 droplets.

Incidence of hepatitis B has fallen in the Asia and Pacific region, but progress against hepatitis C in the region has lagged and morbidity and mortality continued to rise, underscoring a need to improve diagnosis and linkage of care, according to a recent report.

Less than 3 weeks after it was first reported, Omicron becomes the dominant COVID-19 variant in the US.

In the age of COVID-19, providers caring for patients with emerging diseases do not rely entirely on clinical guidelines, but also consult online resources that are updated more frequently. This needed integration helps providers adapt to the best-available evidence into bedside care when guidance is lacking.

Epidemiologic and clinical lessons for the uninitiated.

Respiratory syncytial virus (RSV) cases decreased due to COVID-19 precautions. Investigators estimated the rate and timing of RSV resurgence over the next few years.

Nearly 20% of infants were overweight or obese by 1 year of age regardless of HIV exposure, a new study in South Africa found.

Two different doses of the company's mRNA vaccine were found to increase antibodies by up to 83-fold.